I'm LongbridgeAI, I can summarize articles.LRMR.US gained 2.35% for the week to close at $3.92, outperforming the S&P 500 by about 3.15 percentage points while the benchmark fell 0.8%. The four-day stretch was choppy: prices opened at $3.76 on Tuesday and rallied to $4.08 by the close, hit $4.17 intraday on Wednesday before pulling back, slipped again on Thursday, then recovered on heavy Friday turnover. There were no major catalysts, and daily volume tracked close to the 60-day median.
The Week
LRMR.US gained 2.35% for the week to close at $3.92, outperforming the S&P 500 by about 3.15 percentage points while the benchmark fell 0.8%. The four-day stretch was choppy: prices opened at $3.76 on Tuesday and rallied to $4.08 by the close, hit $4.17 intraday on Wednesday before pulling back, slipped again on Thursday, then recovered on heavy Friday turnover. There were no major catalysts, and daily volume tracked close to the 60-day median.
Analyst Ratings
Eleven brokers currently cover the stock: nine rate it buy and two rate it overweight, with no hold, underweight or sell ratings, and the consensus recommendation is strong buy. The consensus target price is $14.3, roughly 264.8% above spot, with a wide target range of $5 to $26. The name ranks 123rd out of 506 within the biotech industry.
The Week Ahead
The macro calendar is crowded: the New York Fed manufacturing index lands on Tuesday (prior 20.6, forecast 14.75), and Wednesday brings retail sales, retail sales ex-autos, retail control, NAHB housing market index, import price index, and EIA weekly crude and Cushing inventory data. Sentiment around small- and mid-cap biotech names could respond to these prints.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.